Title: | Efficacy and safety of Micafungin in Febrile NeutropenicPatients Treated for Hematological Malignancies |
Authors: | Toubai, Tomomi Browse this author |
Tanaka, Junji Browse this author →KAKEN DB |
Ota, Shuichi Browse this author |
Shigematsu, Akio Browse this author |
Shono, Yusuke Browse this author |
Ibata, Makoto Browse this author |
Hashino, Satoshi Browse this author →KAKEN DB |
Kondo, Takeshi Browse this author →KAKEN DB |
Kakinoki, Yasutaka Browse this author |
Masauzi, Nobuo Browse this author |
Kasai, Masaharu Browse this author |
Iwasaki, Hiroshi Browse this author |
Kurosawa, Mitsutoshi Browse this author |
Asaka, Masahiro Browse this author |
Imamura, Masahiro Browse this author |
Keywords: | febrile neutropenia |
micafungin |
fungal infection |
empirical antifungal therapy |
hematological malignancies |
Issue Date: | 2007 |
Publisher: | The Japanese Society of Internal Medicine |
Journal Title: | Internal Medicine |
Volume: | 46 |
Issue: | 1 |
Start Page: | 3 |
End Page: | 9 |
Publisher DOI: | 10.2169/internalmedicine.46.6021 |
PMID: | 17202726 |
Abstract: | Objective: The purpose of this study was to prospectively evaluate the efficacy and safety of micafungin (MCFG) in empirical therapy for febrile neutropenic patients for whom antibiotic therapy was not effective for hematological malignancies.
Patients and Methods: Twenty-three hematological patients aged 27-82 years with febrile neutropenia for whom antibiotic therapy was not effective were enrolled in this study and responses to treatment were evaluated.
Results: Treatment success rate was 73.9%. Treatment success rates by primary diagnosis were 77.8% in patients with AML, 50.0% in patients with NHL and 87.5% in patients with other diseases. Moreover, MCFG at a dose of 100 mg or more have a tendency to be effective. One or more adverse events occurred in five (27.7%) of the patients during the study. All of these adverse events were below grade 2 toxicity.
Conclusions: Although the number of patients studied was limited, MCFG as a monotherapy seems to be effective and safe as an empirical therapy in patients with febrile neutropenia. However, further investigation using large-scale studies is needed. This study demonstrated the clinical efficacy and safety of MCFG in patients with febrile neutropenia and with hematological malignancies. |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/30236 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|